Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)

NCT07028749 is registered in ClinicalTrials.gov with Marea Therapeutics as lead sponsor.

NCT NCT07028749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)
Lead sponsor
Marea Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
April 30, 2028
Enrollment
316 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia